Login Register
icon_bulk_orderBulk order Acrobiosystems for ChineseChinese
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
SARS-CoV-2  lambda  Delta | Claudin 18.2 | CD20 | CD3 | FcR | IL-2R
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R alpha

IL-2 R alpha

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R,Insulin-Dependent Diabet
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ILA-C52H4 Canine Canine IL-2 R alpha / CD25 Protein, His Tag
ILA-C52H4-structure
ILA-C52H4-sds
ILA-C52H4-elisa_1
ILA-M52H9 Mouse Mouse IL-2 R alpha / CD25 Protein, His Tag
ILA-M52H9-structure
ILA-M52H9-sds
ILA-M52H9-elisa_1
ILA-H82E6 Human Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™
ILA-H82E6-structure
ILA-H82E6-sds
ILA-H82E6-elisa_1
ILA-H52H9 Human Human IL-2 R alpha / CD25 Protein, His Tag
ILA-H52H9-structure
ILA-H52H9-sds
ILA-H52H9-elisa_1
ILA-H52H9-elisa_2
ILA-H5251 Human Human IL-2 R alpha / CD25 Protein, Fc Tag (HPLC-verified)
ILA-H5251-structure
ILA-H5251-sds
ILA-H5251-hplc
ILA-H5251-elisa_1

Part of Bioactivity data

ILA-H82E6-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-2 R alpha, His,Avitag (Cat. No. ILA-H82E6) inhibits the IL-2-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.57-0.81 µg/mL (Routinely tested).

Protocol
ILA-H52H9-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) inhibits the IL-2 dependent proliferation of Mo7e cells. The EC50 for this effect is 0.35-0.77 µg/mL (Routinely tested).

Protocol
ILA-H52H9-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 29.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
ILA-H82E6-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human IL-2 R alpha, His,Avitag (Cat. No. ILA-H82E6) on SA Biosensor, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 70.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Synonym Name

IL2RA,CD25,p55,IL2-RA,IL-2-RA

Background

Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

Clinical and Translational Updates

Related Molecule

IL-2

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap